Lactobacillus rhamnosus LRa05 improves lipid accumulation in mice fed with a high fat diet via regulating intestinal microbiota, reducing glucose content and promoting liver carbohydrate metabolism

To illustrate the effect of Lactobacillus rhamnosus LRa05 on anti-obesity, and through the analysis of gut microbiota and liver metabolomics, we investigated alterations in gut microbiota and liver metabonomic phenotype by 16S ribosomal RNA gene sequencing and ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry in C57BL/6J male mice orally administered with LRa05 for 8 weeks. The body weight, serum lipid levels and lipid accumulation of liver cells and epididymal fat tissues in the HFD-fed mice were inhibited after treatment with LRa05 at 1 × 109 CFU·day-1 per mouse. LRa05 also reshaped gut microbiota, reduced abundance of pro-pathogen bacterial Streptococcus, suppressed glucose content in blood and liver, promoted liver carbohydrate and energy metabolism. Moreover, the positive relationship between Intestinimonas and palmitoyl ethanolamide, and the negative relationship between Enterorhabdus and vitamin B2 were discovered. Therefore, LRa05 could be potential anti-obesity probiotics in further intervention.